CONCORDBIO - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 2.8
| Stock Code | CONCORDBIO | Market Cap | 12,162 Cr. | Current Price | 1,163 ₹ | High / Low | 2,452 ₹ |
| Stock P/E | 37.8 | Book Value | 174 ₹ | Dividend Yield | 0.93 % | ROCE | 28.4 % |
| ROE | 21.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,327 ₹ | DMA 200 | 1,538 ₹ |
| Chg in FII Hold | -0.45 % | Chg in DII Hold | 0.03 % | PAT Qtr | 62.9 Cr. | PAT Prev Qtr | 42.6 Cr. |
| RSI | 20.9 | MACD | -56.5 | Volume | 69,549 | Avg Vol 1Wk | 1,21,277 |
| Low price | 1,100 ₹ | High price | 2,452 ₹ | PEG Ratio | 1.41 | Debt to equity | 0.00 |
| 52w Index | 4.63 % | Qtr Profit Var | -36.3 % | EPS | 30.7 ₹ | Industry PE | 28.2 |
📊 Concord Biotech (CONCORDBIO) has solid fundamentals but its technical indicators show significant weakness. It is not an ideal candidate for swing trading at present, though oversold conditions may offer a short-term rebound opportunity.
✅ Optimal Entry Price: 1,120–1,140 ₹ (near strong support and close to 52-week low)
🚪 Exit Strategy if Holding: Consider exiting near 1,300–1,350 ₹ (around 50 DMA resistance) or if RSI recovers above 40.
Positive
- 💡 Strong ROCE (28.4%) and ROE (21.4%) indicate efficient capital allocation.
- 📈 EPS of 30.7 ₹ supports earnings strength.
- 🏦 Debt-free balance sheet (Debt-to-equity: 0.00).
- 💰 Dividend yield of 0.93% provides investor confidence.
Limitation
- ⚠️ RSI at 20.9 indicates oversold conditions and weak momentum.
- 📉 MACD at -56.5 signals strong bearish trend.
- 🔻 Quarterly profit variation (-36.3%) highlights earnings volatility.
- 📊 Current price (1,163 ₹) is well below both 50 DMA (1,327 ₹) and 200 DMA (1,538 ₹), showing technical weakness.
Company Negative News
- 📉 Decline in FII holdings (-0.45%) suggests reduced foreign investor confidence.
- 📊 Sharp drop in quarterly profit compared to previous quarter.
Company Positive News
- 📈 PAT improved from 42.6 Cr. to 62.9 Cr. sequentially, showing recovery despite volatility.
- 📊 Slight increase in DII holdings (+0.03%) reflects domestic support.
Industry
- 🏭 Industry P/E at 28.2 is lower than Concord Biotech’s P/E (37.8), indicating premium valuation.
- 📈 Biotech sector remains promising with long-term demand, though short-term volatility is high.
Conclusion
🔎 Concord Biotech is fundamentally strong but technically weak in the short term. Swing traders should be cautious, as RSI and MACD show bearish signals. Entry near 1,120–1,140 ₹ may be considered only if momentum indicators improve. Exit near 1,300–1,350 ₹ is advisable for current holders to mitigate downside risk.